Lupin buys anti cholesterol drug rights for $39 mn

A file picture of Dr. Desh Bandhu Gupta, Chairman, Lupin Ltd at a press conference at Mumbai. Photo: Paul Noronha.  

Indian pharmaceuticals major Lupin on Tuesday said that it had acquired the rights for Antara, a drug to treat high blood cholesterol and high triglycerides, for $38.61 million from the US-based Oscient Pharmaceuticals.

The rights for the drug, along with related assets and inventories, have been acquired under the procedures of the US Bankruptcy Court, the company said in a regulatory filing with the Bombay Stock Exchange (BSE).

The market for similar fenofibrate drugs was $1.9 billion over the past 12 months, out of which Antara had recorded sales worth $70 million, the Lupin statement said.

“Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately,” said Vinita Gupta, group president and chief financial officer for Lupin.

The company had previously filed its own application for fenofibirte capsules but had sold the same to another Indian pharmaceuticals major, Dr. Reddy’s Laboratories, on Sep 21, the company said.

Lupin had registered a consolidated revenue of Rs.3,914.5 crore ($783 million) in 2008—09, while its profit after tax stood at Rs.501.5 crore ($100 million).

This article is closed for comments.
Please Email the Editor

Printable version | Nov 28, 2020 7:02:18 PM |

Next Story